Needham & Company LLC reiterated their buy rating on shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in a research note published on Tuesday. They currently have a $64.00 price objective on the stock.

Several other equities research analysts have also commented on IONS. Jefferies Group LLC restated an underperform rating and set a $18.00 target price (up previously from $17.00) on shares of Ionis Pharmaceuticals in a research report on Thursday, August 10th. Laidlaw restated a buy rating and set a $65.00 target price on shares of Ionis Pharmaceuticals in a research report on Monday, August 14th. BMO Capital Markets upped their target price on Ionis Pharmaceuticals from $67.00 to $69.00 and gave the company an outperform rating in a research report on Monday, August 14th. Sanford C. Bernstein assumed coverage on Ionis Pharmaceuticals in a research report on Thursday, July 27th. They set a market perform rating and a $57.00 target price on the stock. Finally, Stifel Nicolaus restated a hold rating and set a $50.00 target price on shares of Ionis Pharmaceuticals in a research report on Friday, October 13th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $50.04.

Ionis Pharmaceuticals (NASDAQ IONS) traded up 1.15% during trading on Tuesday, hitting $64.39. The stock had a trading volume of 1,631,810 shares. The firm has a market capitalization of $8.01 billion, a P/E ratio of 309.57 and a beta of 3.12. The stock has a 50 day moving average of $56.15 and a 200 day moving average of $50.31. Ionis Pharmaceuticals has a one year low of $24.58 and a one year high of $65.51.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Tuesday, August 8th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03). Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The business had revenue of $104.15 million for the quarter, compared to the consensus estimate of $93.29 million. During the same quarter in the previous year, the company earned ($0.47) EPS. The firm’s revenue for the quarter was up 170.7% on a year-over-year basis. Equities research analysts expect that Ionis Pharmaceuticals will post ($0.16) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Ionis Pharmaceuticals, Inc. (IONS) Earns Buy Rating from Needham & Company LLC” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/20/ionis-pharmaceuticals-inc-ions-earns-buy-rating-from-needham-company-llc.html.

In other news, SVP C Frank Bennett sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $59.29, for a total value of $592,900.00. Following the transaction, the senior vice president now owns 25,041 shares in the company, valued at $1,484,680.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Patrick R. O’neil sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $55.00, for a total value of $55,000.00. Following the completion of the transaction, the senior vice president now owns 10,633 shares in the company, valued at approximately $584,815. The disclosure for this sale can be found here. In the last quarter, insiders sold 79,268 shares of company stock worth $4,414,545. Corporate insiders own 2.13% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Parallel Advisors LLC lifted its holdings in shares of Ionis Pharmaceuticals by 62.8% in the second quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock valued at $109,000 after purchasing an additional 800 shares in the last quarter. Aviva PLC bought a new position in shares of Ionis Pharmaceuticals in the second quarter valued at approximately $10,187,000. Credit Suisse AG lifted its holdings in shares of Ionis Pharmaceuticals by 79.2% in the first quarter. Credit Suisse AG now owns 385,145 shares of the company’s stock valued at $15,483,000 after purchasing an additional 170,192 shares in the last quarter. Allen Investment Management LLC lifted its holdings in shares of Ionis Pharmaceuticals by 64.7% in the second quarter. Allen Investment Management LLC now owns 15,652 shares of the company’s stock valued at $796,000 after purchasing an additional 6,147 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Ionis Pharmaceuticals by 21.4% in the second quarter. Russell Investments Group Ltd. now owns 20,077 shares of the company’s stock valued at $1,021,000 after purchasing an additional 3,538 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.